Data up to 8-years for Roche ’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis

Basel, 13 October 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new long-term data that reinforce the benefit of early initiation and ongoing treatment of OCREVUS® (ocrelizumab) on disability progression in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS), as well as safety outcomes for an analysis of shorter 2-hour infusion in minority populations. OCREVUS data from all clinical trials consistently show a favourable benefit-risk profile over eight years. Roche and research partners will also present four late-breaking abstracts to share the latest data regarding COVID-19 and vaccine response in patients treated with OCREVUS. These data are being presented virtually at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).“Many neurologists have had first-hand experience with OCREVUS over eight years in clinical trials and witnessed the consistently favourable efficacy and safety outcomes in RMS and PPMS, especially the reductions in progression to disability when given early in the disease,” said Levi Garraway, M.D., Ph.D. Roche's Chief Medical Officer and Head of Global Product Development. “Additionally, the new safety analysis of the shorter two-hour OCREVUS infusion is encouraging particularly for groups that are often underrepresented in clinical trials. We continue our commitment to diversity and health equity in clinical trial participation and access to treatm...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

The cancer organization today largely reinstated its former advice that men with low-risk prostate cancer be offered active surveillance as the lone'preferred'initial treatment option.News Alerts
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
No abstract available
Source: The Journal of ECT - Category: Psychiatry Tags: Commentaries Source Type: research
Conclusions Our results confirm earlier prospective and retrospective data regarding the efficacy and importance of C/M-ECT as relapse prevention. After treatment discontinuation, close monitoring of early warning signs for relapse is crucial, especially in the first few months. With the COVID-19 pandemic continuing, our data provide an indication of the necessity to ensure adequate care and access to ECT not only for the acutely ill but also for the vulnerable patients who are depending on C/M-ECT.
Source: The Journal of ECT - Category: Psychiatry Tags: Original Studies Source Type: research
Conclusions Greater public education is needed about ECT, particularly in the United States. Misperceptions and lack of knowledge may hinder utilization of ECT in India, China, and the United States.
Source: The Journal of ECT - Category: Psychiatry Tags: Original Studies Source Type: research
No abstract available
Source: The Journal of ECT - Category: Psychiatry Tags: Letters to the Editor Source Type: research
No abstract available
Source: The Journal of ECT - Category: Psychiatry Tags: Letters to the Editor Source Type: research
Cancer Gene Therapy, Published online: 01 December 2021; doi:10.1038/s41417-021-00402-9Correction: microRNA-let-7e in serum-derived exosomes inhibits the metastasis of non-small-cell lung cancer in a SUV39H2/LSD1/CDH1-dependent manner
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
While some clinicians were worried about the mandate, in the end, they're coping just fine.
Source: Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news
Jeffrey A. SingerA Food and Drug Administration Advisory Panel justapproved, narrowly, the Merck antiviral drug Molnupiravir. This is just step one. We now have to wait for the FDA to decide on emergency use authorization.The U.K. approved Molnupiravir on November 4.Merck applied to the FDA for approval on October 11. Vaccines are the best long ‐​term defense against COVID-19, but antivirals are the best first‐​line defense, especially when new variants can develop that escape the immunity provided by vaccines.Rather than wait weeks for the vaccine to take effect, antivirals —like antibiotics—work immed...
Source: Cato-at-liberty - Category: American Health Authors: Source Type: blogs
West Virginia's coronavirus czar, West Virginia University's Dr. Clay Marsh, said Tuesday that the emergence of the new omicron variant of Covid-19 underscores the need for everyone to be vaccinated and for the fully vaccinated to get their boosters. In a news conference with Gov. Jim Justice and other state officials, Marsh said there have been no cases of the omicron variant identified yet in West Virginia but that state officials were on alert. There also have been no cases yet identified in…
Source: Health Care News Headlines - Category: Health Management Authors: Source Type: news
More News: Allergy & Immunology | Alzheimer's | Australia Health | Autism | Avonex | Biotechnology | Brain | Brain Cancers | Cancer | Cancer & Oncology | Cancer Vaccines | Clinical Trials | COVID-19 | Diabetes | Disability | Endocrinology | Infectious Diseases | International Medicine & Public Health | Japan Health | Men | Middle East Health | Multiple Sclerosis | Muscular Dystrophy | Neurology | Neuroscience | Opthalmology | Partnerships | Pharmaceuticals | Politics | Rebif | Reflex Sympathetic Dystrophy | Science | Stem Cell Therapy | Stem Cells | Study | Switzerland Health | UK Health | USA Health | Vaccines | WHO